Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia

Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).

Stein says all patients with AML have a multitude of mutations that are causing their disease, and that targeting single mutations such as FLK3 and IDH may not be enough to make an impact. He adds that combining agents that, for example, target both of those mutations could very well be the future of the treatment paradigm.